Lars Gunnar Larsson

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. Tabor V, Bocci M, Alikhani N, Kuiper R, Larsson L. MYC synergizes with activated BRAFV600E in mouse lung tumor development by suppressing senescence. Cancer Res. 2014;74:4222-9 pubmed publisher
    ..These findings contribute to our understanding of the neoplastic transformation process, with implications for future treatment strategies. ..
  2. Castell A, Larsson L. Targeting MYC Translation in Colorectal Cancer. Cancer Discov. 2015;5:701-3 pubmed publisher
  3. Castell A, Yan Q, Fawkner K, Hydbring P, Zhang F, Verschut V, et al. A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation. Sci Rep. 2018;8:10064 pubmed publisher
    ..Since MYCMI-6 does not affect MYC expression, it is a unique molecular tool to specifically target MYC:MAX pharmacologically and it has good potential for drug development. ..
  4. Larsson L, Henriksson M. The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy. Exp Cell Res. 2010;316:1429-37 pubmed publisher
  5. Larsson L. Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence. Semin Cancer Biol. 2011;21:367-76 pubmed publisher
    ..This can hopefully form the basis for a "pro-senescence therapy" strategy to combat cancer in the future. ..
  6. Hydbring P, Castell A, Larsson L. MYC Modulation around the CDK2/p27/SKP2 Axis. Genes (Basel). 2017;8: pubmed publisher
    ..Finally, we describe how the MYC/CDK2/p27/SKP2 axis impacts on tumor development and discuss possible ways to interfere therapeutically with this system to improve cancer treatment. ..